News and Announcements
Appointment of Taiwan Distributor
- Published December 15, 2020 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Highlights
• Appointment of J&H Technology Co Ltd as Optiscan’s exclusive pre-clinical distributor for Taiwan
• J&H Technology is a distributor of leading United States and European pre-clinical equipment
Optiscan Imaging Limited (ASX: OIL) (‘the Company’ or ‘Optiscan’) announces that it has appointed J&H Technology as its exclusive distributor in Taiwan for the FIVE2(ViewnVivo) in the pre-clinical research market. This appointment follows the appointment of two (2) China distributors in Shanghai and Guangzhou in 2019 and a new distributor in North America in 2020. Taiwan represents an attractive market for the FIVE2 (ViewnVivo), being consistently ranked as the top knowledge economy in Asia, with its biomedical sector identified as one of the five pillar industries for its national development.
J&H Technology was founded in 2000 and has approximately 25 staff. It is a distributor for leading United States and European pre-clinical suppliers including ThermoFisher Scientific, PerkinElmer and Miltenyi Biotec.
Optiscan’s Executive Chairman Darren Lurie, said:
“The appointment of J&H Technology continues the expansion of our international distribution arrangements for the FIVE2 (ViewnVivo) in the pre-clinical research market. We are very pleased to have such a well-credentialled partner in an attractive market.”
About Optiscan Imaging Limited (ASX:OIL)
OptiScan (ASX:OIL) is an Australian listed company and a pioneer in the development and application of endomicroscopic imaging technologies for medical markets. Our multi-patented confocal imaging technology can be used for both cancer screening and tumour margin detection in cancer surgery. Our device enables real-time, in vivo imaging at the cellular level in clinical applications, providing a “digital” biopsy. The benefits of this “digital” biopsy include monitoring of early stage disease, earlier identification of pre-cancer and the potential to reduce the time doctors, patients and operating theatres are required to wait for pathology results, the number of repeat surgeries and actual biopsies required.
Company Updates
The Index Approach in Early-Stage Venture Capital: Reconsidered
The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]
The Future Is Now: The Evolution of Dealflow with Wholesale Investor
If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]
Investability of a Startup: A Comprehensive Guide for Angels and High-Net Worth Investors
Venturing into the Startup Scene Let’s dive into the intriguing world of startups. It’s a thrilling ride, isn’t it? Like finding a pearl in an ocean, spotting a promising startup amidst a sea of businesses is no easy task. This guide aims to light the way, focusing on the “The Investability of a Startup: 7 […]
Backed By Leading Investment Groups and Family Offices
